Novartis CEO: Sales on track to match 2011; CDC panel recommends Pfizer vax for another use;

 @FiercePharma: AstraZeneca's Brilinta = lower healthcare costs, even at brand prices, finds cost-based analysis of PLATO data. More | Follow @FiercePharma

> Novartis ($NVS) CEO Joe Jimenez said the Swiss drugmaker is on track to match last year's sales, despite the impending loss of exclusivity on its big-selling blood pressure drug Diovan. Report

> The Centers for Disease Control and Prevention's vaccine panel recommended Pfizer's ($PFE) Prevnar 13 for adults with immunocompromising conditions; the company continues to press for a recommendation in all adults 50 years and older. Release

> The FDA approved Pfizer's Lyrica drug, its second-best seller, to fight pain caused by spinal cord injuries. Item

> Valeant Pharmaceuticals expects its 2012 results to hit the top end of its previously forecast EPS of $4.45 to $4.70. News

> The Spanish government has increased co-payments on chronic-disease drugs by as much as 56%. Article

> The pharmaceuticals wholesale and distribution market will reach $747 billion by 2014, the market research firm Visiongain said. Story

Biotech News

 @FierceBiotech: See the faces of biotech leaders at BIO2012 in our convention slideshow. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Interesting to note that if the ACA is tossed out by the Supremes, there goes 12 years of exclusivity for biologics and biosimilars pathway. Poof. | Follow @JohnCFierce

 @RyanMFierce: My take from BIO 2012 on how the pharma herd faces hurdles with pricey new drugs. Report | Follow @RyanMFierce

> Pozen shares slide after FDA questions study for aspirin combo. More

> House rushes through approval of new PDUFA legislation. News

> Onyx clears big hurdle in high-stakes gamble on early carfilzomib approval. Article

> FDA panel turns thumbs down on Sanofi's anti-clotting drug. Story

Medical Devices News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: EndoGastric pulled in another $13M in new venture finding for a device designed to help treat chronic acid reflux. Press release | Follow @MarkHFierce

 @DamianFierce: Lawmakers, device industry on the same page as FDA user fee clears House, moves toward adoption. Article | Follow @DamianFierce

> House votes to extend medical device user fees. More

> Roche Diagnostics commits $300M to Indianapolis expansion. Story

> United Arab Emirates invests in med device tech for school clinics. Item

CRO News

 @NesaNFierce: Not shocked that the Philippines and Indonesia are eyed as emerging leaders in outsourcing. Population means a lot. More | Follow @NesaNFierce

> Can Russia emerge as a global biotech and manufacturing leader? More

> Filling services help Dalton seal manufacturing deal with Clarity. Article

> Biopharma looks at pros and cons of CMOs when debating in-house versus outsourcing. News

Pharma Manufacturing News

> Shasun cutting costs with Indian intermediates plant. Article

> Bard, Sartorius invest nearly $70M in Puerto Rico plants. Story

> CSL confirms convulsions appear tied to Fluvax manufacturing. More

Vaccines News

> HPV DNA vax should enter the clinic in 2013. More

> Therapeutic cancer vaccines: Optimism for the future at BIO2012. Article

> Anthrax vax to move into new Phase II trials. Story

> Genocea's HSV-2 vax to hit the clinic. News

And Finally... Brain research confirms that love and sexual desire aren't the same thing. Report